Nuggehally R Srinivas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5156714/publications.pdf

Version: 2024-02-01

251	3,594	136950	206112
papers	citations	32 h-index	48 g-index

252	252	252	3694
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A concise review of bioanalytical methods of small molecule immunoâ€oncology drugs in cancer therapy. Biomedical Chromatography, 2021, 35, e4996.	1.7	3
2	Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection?. Future Medicinal Chemistry, 2021, 13, 157-171.	2.3	13
3	Enantioselective inÂvitro ADME, absolute oral bioavailability, and pharmacokinetics of (â^')-lumefantrine and (+)-lumefantrine in mice. Xenobiotica, 2021, 51, 202-209.	1.1	1
4	Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients. Drug Metabolism Letters, 2021, 14, 54-65.	0.8	4
5	Pronounced influence of presystemic metabolism on the metabolic disposition of imrecoxib in renally impaired patients. European Journal of Clinical Pharmacology, 2020, 76, 469-471.	1.9	2
6	Relevance of preclinical rodent pharmacokinetics in the selection of a companion antibiotic for combining with beta-lactamase inhibitor. Xenobiotica, 2020, 50, 815-821.	1.1	0
7	A review of bioanalytical methods for chronic lymphocytic leukemia drugs and metabolites in biological matrices. Biomedical Chromatography, 2020, 34, e4742.	1.7	1
8	ZYBT1, a potent, irreversible Brutonâ€™s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer. Pharmacology Research and Perspectives, 2020, 8, e00565.	2.4	11
9	Critical Assessment of Pharmacokinetic Drugâ€“Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Safety, 2020, 43, 711-725.	3.2	37
10	Protein Binding and Stability of Drug Candidates: The Achillesâ€™ Heel in In Vitro Potency Assays. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 427-432.	1.6	1
11	Novel methodology to perform incurred sample reanalysis on dried blood spot cards: Experimental data using darolutamide and filgotinib. Biomedical Chromatography, 2020, 34, e4938.	1.7	2
12	Simultaneous determination of colchicine and febuxostat in rat plasma: Application in a rat pharmacokinetic study. Biomedical Chromatography, 2020, 34, e4939.	1.7	9
13	Incurred sample reanalysis of cefuroxime in rabbit ocular tissuesâ€”A case study. Biomedical Chromatography, 2020, 34, e4737.	1.7	4
14	Impact of collagen-induced arthritis on the pharmacokinetic disposition of voriconazole, a widely used antifungal agent: in vitro and in vivo investigations in DBA/1J mice. Xenobiotica, 2019, 49, 698-707.	1.1	0
15	Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles. Drug Research, 2019, 69, 32-39.	1.7	2
16	Combination of flavonoids with azole drugs for fungal infections: key pharmacokinetic challenges. Future Microbiology, 2019, 14, 733-738.	2.0	3
17	A sensitive quantitative assay for the determination of propafenone and two metabolites, 5â€hydroxypropafenone and Nâ€depropylpropafenone, in human K2EDTA plasma using LCâ€“MS/MS with ESI operated in positive mode. Biomedical Chromatography, 2019, 33, e4671.	1.7	0
18	Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs. Drug Development and Industrial Pharmacy, 2019, 45, 1459-1467.	2.0	3

#	Article	IF	Citations
19	Prediction of Human Pharmacokinetics of Fomepizole from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles. AAPS PharmSciTech, 2019, 20, 221.	3.3	1
20	Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 719-721.	1.6	1
21	Simultaneous determination of bendamustine and Î³-hydroxybendamustine in mice dried blood spots and its application in a mice pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 168-174.	2.8	6
22	Use of Cocktail Probe Drugs for Indexing Cytochrome P450 Enzymes in Clinical Pharmacology Studies â€“ Review of Case Studies. Drug Metabolism Letters, 2019, 13, 3-18.	0.8	13
23	Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. Xenobiotica, 2019, 49, 1202-1208.	1.1	1
24	Incurred sample reanalysis in drug discovery bioanalysis. Biomedical Chromatography, 2019, 33, e4430.	1.7	10
25	Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. Clinical Drug Investigation, 2019, 39, 105-107.	2.2	1
26	Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. European Journal of Pharmaceutical Sciences, 2019, 130, 107-113.	4.0	6
27	Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of ZYTP1, a novel poly (ADP-ribose) polymerase inhibitor. Xenobiotica, 2019, 49, 1164-1172.	1.1	2
28	Review of DBS methods as a quantitative tool for anticancer drugs. Biomedical Chromatography, 2019, 33, e4445.	1.7	19
29	Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension. Xenobiotica, 2019, 49, 415-421.	1.1	5
30	Strategy for the Prediction of Steady-State Exposure of Digoxin to Determine Drugâ€“Drug Interaction Potential of Digoxin With Other Drugs in Digitalization Therapy. American Journal of Therapeutics, 2019, 26, e54-e65.	0.9	1
31	Lack of Translatable Proinflammatory Cytokines in Cerebrospinal Fluid in Rats With Increased Hyperalgesia With or Without Fentanyl Treatment. Anesthesia and Analgesia, 2018, 126, 2150.	2.2	1
32	Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 373-382.	1.6	8
33	Letter: high oral dose of taurine for portal hypertension in cirrhotic patientsâ€”some clinical pharmacology considerations. Alimentary Pharmacology and Therapeutics, 2018, 47, 861-862.	3.7	0
34	Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. Clinical Pharmacokinetics, 2018, 57, 1385-1398.	3.5	51
35	Reduced Ketobemidone Usage in Quadratus Lumborum Block Patients After Cesarean Delivery: Clinical Pharmacology Views. Anesthesia and Analgesia, 2018, 127, 311-311.	2.2	3
36	Antiretroviral Therapy With Efavirenz in HIVâ€Infected Pregnant Women: Understanding the Possible Mechanisms for Drugâ€“Drug Interaction. Clinical Pharmacology and Therapeutics, 2018, 103, 570-570.	4.7	1

#	Article	IF	Citations
37	Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure. Clinical Therapeutics, 2018, 40, 456-468.e1.	2.5	2
38	Influence of Morbid Obesity on the Clinical Pharmacokinetics of Various Anti-Infective Drugs: Reappraisal Using Recent Case Studiesâ€"Issues, Dosing Implications, and Considerations. American Journal of Therapeutics, 2018, 25, e224-e246.	0.9	10
39	Reappraisal and perspectives of clinical drugâ€"drug interaction potential of Î±-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica, 2018, 48, 89-108.	1.1	49
40	Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia. Xenobiotica, 2018, 48, 37-44.	1.1	10
41	Ponesimod, a selective sphingosine 1-phosphate (S1P₁) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition. Xenobiotica, 2018, 48, 442-451.	1.1	14
42	Consequences of daily corticosteroid dosing with or without pre-treatment with quinidine on the in vivo cytochrome P450 2D (CYP2D) enzyme in rats: effect on O-demethylation activity of dextromethorphan and expression levels of CYP2D1 mRNA. Xenobiotica, 2018, 48, 1-10.	1.1	7
43	Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models. Xenobiotica, 2018, 48, 148-156.	1.1	3
44	Stereoselective and nonstereoselective pharmacokinetics of rabeprazole â€" an overview. Xenobiotica, 2018, 48, 422-432.	1.1	8
45	Review of HPLC and LCâ€"MS/MS assays for the determination of various nonsteroidal antiâ€androgens used in the treatment of prostate cancer. Biomedical Chromatography, 2018, 32, e4034.	1.7	9
46	Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers. Clinical Pharmacokinetics, 2018, 57, 87-102.	3.5	29
47	Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARÎ±Î³ Agonist, in Healthy Adult Subjects. Clinical Drug Investigation, 2018, 38, 57-65.	2.2	11
48	A review of bioanalytical quantitative methods for selected sphingosine 1â€phosphate receptor modulators. Biomedical Chromatography, 2018, 32, e4109.	1.7	4
49	Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion. Xenobiotica, 2018, 48, 945-957.	1.1	12
50	Arenobufagin: A potential novel opportunity for prostate cancer treatment â€" Intriguing mechanistic data but some questions on in vivo translatability. Pharmacological Research, 2018, 128, 400-401.	7.1	1
51	Preclinical evaluation of saroglitazar magnesium, a dual PPAR-Î±/Î³ agonist for treatment of dyslipidemia and metabolic disorders. Xenobiotica, 2018, 48, 1268-1277.	1.1	7
52	LCâ€ESIâ€MS/MS determination of 4â€methylpyrazole in dog plasma and its application to a pharmacokinetic study in dogs. Biomedical Chromatography, 2018, 32, e4065.	1.7	1
53	Key Pharmacokinetic Essentials of Fixed-Dosed Combination Products: Case Studies and Perspectives. Clinical Pharmacokinetics, 2018, 57, 419-426.	3.5	9
54	Extrapolation of pharmacokinetic interaction data of proton pump inhibitors obtained in healthy subjects for oral targeted therapies in cancer patients. International Journal of Pharmacokinetics, 2018, 3, 93-97.	0.5	0

#	Article	IF	Citations
55	In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Drug Metabolism Letters, 2018, 12, 101-116.	0.8	6
56	Regression modeling strategy for prediction of AUC of evogliptin, a novel dipeptidyl peptidase IV inhibitor in humans, using single dose PK data. International Journal of Pharmacokinetics, 2018, 3, 23-38.	0.5	0
57	Opposite effects of acute kidney injury on pharmacokinetics of renally and hepatobiliary excreted drugs. International Journal of Pharmacokinetics, 2018, 3, 81-90.	0.5	0
58	Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. Xenobiotica, 2017, 47, 354-368.	1.1	27
59	Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir. American Journal of Therapeutics, 2017, 24, e405-e418.	0.9	5
60	Stereoselective Conversion of Ketoprofen in Men Versus Women from Two Different Oral Dosage Formulations: Observations and Introspection of the Pharmacokinetic Data. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 165-166.	1.6	1
61	Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infectious Diseases, 2017, 49, 483-492.	2.8	24
62	A sensitive quantitative assay for the determination of propafenone and two metabolites, 5â€hydroxypropafenone and Nâ€depropylpropafenone, in human K2EDTA plasma using LCâ€“MS/MS with ESI operated in positive mode. Biomedical Chromatography, 2017, 31, e3967.	1.7	6
63	Preclinical pharmacokinetics of novel trioxane antimalarial drug (99/411) â€“ several unanswered questions and development perspectives. Biomedical Chromatography, 2017, 31, e3938.	1.7	0
64	One should avoid retro-orbital pharmacokinetic sample collections for intranasal dosing in rats: Illustration of spurious pharmacokinetics generated for anti-migraine drugs zolmitriptan and eletriptan. European Journal of Pharmaceutical Sciences, 2017, 106, 87-93.	4.0	0
65	Improved oral bioavailability and brain accumulation of afatinib due to dual inhibition of the efflux mechanisms of BCRP and Pgp transporters â€”What next?. Pharmacological Research, 2017, 123, 143.	7.1	1
66	Severe metabolic impairment with increasing age for CYP3A and CYP2D substrates in rats: Possible consequences for drug development. Biomedical Chromatography, 2017, 31, e4009.	1.7	0
67	Pharmacodynamics of Insulin Preparations Administered in Different Subcutaneous Injection Sites: Are There Differences Between Healthy Subjects Versus Diabetic Patients?. Clinical Drug Investigation, 2017, 37, 881-884.	2.2	1
68	Letter: sublingual dosing of tacrolimus in transplant patientsâ€•interesting concept to overcome first pass effects. Alimentary Pharmacology and Therapeutics, 2017, 46, 79-80.	3.7	2
69	Sensitive and specific LCâ€ESIâ€MS/MS method for determination of ZYDPLA1, a novel longâ€acting dipeptidyl peptidase 4 inhibitor in rat plasma: An application for toxicokinetic study in rats. Biomedical Chromatography, 2017, 31, e3984.	1.7	2
70	Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 915-933.	1.6	59
71	Comments on:â€œInÂvitro and inÂvivo pharmacokinetics and toxicity evaluation of curcumin incorporated titanium dioxide nanoparticles forÂbiomedical applicationsâ€• Chemico-Biological Interactions, 2017, 277, 145.	4.0	1
72	Letter: <scp>CYP</scp>2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxibâ€induced small bowel injury. Alimentary Pharmacology and Therapeutics, 2017, 46, 706-707.	3.7	1

#	Article	IF	Citations
73	Comments on: â€œPopulation Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertensionâ€• European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 1019-1021.	1.6	1
74	Letter: clinical response to pioglitazone in nonalcoholic steatohepatitis [<scp>NASH</scp>] treatmentâ€”use of pharmacokinetic surrogate. Alimentary Pharmacology and Therapeutics, 2017, 46, 470-471.	3.7	1
75	Intravenous-to-oral switch in antimicrobial therapy: clinical pharmacology considerations and perspectives. Future Microbiology, 2017, 12, 847-851.	2.0	4
76	Comment on: â€œA Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-aspartate Angiotensin I in Healthy Subjectsâ€• Drugs in R and D, 2017, 17, 241-242.	2.2	1
77	Comment on: â€œModeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancerâ€• Clinical Pharmacokinetics, 2017, 56, 211-212.	3.5	1
78	Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 677-688.	1.6	19
79	Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine. Biomedical Chromatography, 2017, 31, e3807.	1.7	32
80	Interspecies scaling of urinary excretory amounts of nine drugs belonging to different therapeutic areas with diverse chemical structures â€“ accurate prediction of the human urinary excretory amounts. Xenobiotica, 2017, 47, 112-118.	1.1	3
81	An LCâ€“MS/MS assay for the quantitative determination of 2â€pyridyl acetic acid, a major metabolite and key surrogate for betahistine, using lowâ€volume human K₂EDTA plasma. Biomedical Chromatography, 2017, 31, e3790.	1.7	1
82	Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica, 2017, 47, 1015-1026.	1.1	18
83	Review of the bioanalytical methods for the determination of methotrexate and its metabolites in in vitro, preclinical and clinical studies: Case studies and perspectives. Biomedical Chromatography, 2017, 31, e3849.	1.7	7
84	Review of Pharmacokinetic Data of Different Drug Classes in Goto-Kakizaki Rats, a Non-obese Model for Type 2 Diabetes Mellitus: Case Studies and Perspectives. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 173-182.	1.6	4
85	Human biliary amount prediction using simple, bile flow-rate corrected and uridine diphosphate glucuronosyltransferase activity corrected allometric methods. International Journal of Pharmacokinetics, 2017, 2, 173-182.	0.5	0
86	Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters. General Physiology and Biophysics, 2016, 35, 243-258.	0.9	18
87	A comprehensive review of the published assays for the quantitation of the immunosuppressant drug mycophenolic acid and its glucuronidated metabolites in biological fluids. Biomedical Chromatography, 2016, 30, 721-748.	1.7	15
88	Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?. Cancer Chemotherapy and Pharmacology, 2016, 78, 1097-1098.	2.3	14
89	Enantioselective Pharmacokinetics of Bambuterol in Preclinical Species: Does S-bambuterol Influence the Clearance of the R-antipode?. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 197-198.	1.6	0
90	Clinical Drugâ€“Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 469-503.	1.6	9

#	Article	IF	Citations
91	Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy. Future Microbiology, 2016, 11, 485-490.	2.0	1
92	Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease â€“ should one consider disease location?. Alimentary Pharmacology and Therapeutics, 2016, 44, 771-772.	3.7	2
93	Verapamil and pristimerin pharmacokinetic drugâ€“drug interaction study in rats â€“ perspectives. Biomedical Chromatography, 2016, 30, 2074-2074.	1.7	0
94	Availability of plethora of bioanalytical assays for several commonly prescribed drugs â€“ a problem of plenty: perspectives. Biomedical Chromatography, 2016, 30, 668-669.	1.7	0
95	Prostaglandin E1 therapy with alprostadil and risk reduction in early hepatic cellular carcinoma after liver transplantation. Alimentary Pharmacology and Therapeutics, 2016, 43, 172-173.	3.7	3
96	Letter: vonoprazan, a long-lasting acid suppressor of the gastric H+, K+-ATPases with - implications for renal H+, K+-ATPases. Alimentary Pharmacology and Therapeutics, 2016, 43, 442-443.	3.7	2
97	Letter: ileal bile acid transporter inhibition - is there a potential for drug-drug interaction?. Alimentary Pharmacology and Therapeutics, 2016, 43, 750-751.	3.7	1
98	Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 1239-1240.	3.7	1
99	Letter: probing the consequences of potent acid inhibition by vonoprazan. Alimentary Pharmacology and Therapeutics, 2016, 44, 304-305.	3.7	1
100	Is There Saturation in the Conversion of Baicalein to Baicalin After Oral Chewable Tablets: Retrospective Evaluation of the Human Pharmacokinetic Data?. Clinical Drug Investigation, 2016, 36, 1075-1076.	2.2	2
101	Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. Clinical Neuropharmacology, 2016, 39, 169-177.	0.7	3
102	Is the inhibition of the liver uptake and biliary excretion, via transporters, the likely mechanism for the increased exposure of vitexinâ€2â€²â€²â€Oâ€rhamnoside with bile salts in rats?. Biomedical Chromatography, 2016, 30, 1701-1702.	1.7	0
103	Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms. Drugs in R and D, 2016, 16, 141-148.	2.2	28
104	Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of C trough- over C max-Derived Linear Regression Models. Drugs in R and D, 2016, 16, 69-79.	2.2	15
105	A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidaseâ€4 (DPP4) inhibitor, utilized for the characterization of the drug. Biomedical Chromatography, 2016, 30, 749-771.	1.7	13
106	Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode. Biomedical Chromatography, 2016, 30, 1900-1907.	1.7	3
107	Is there a differential conversion of artesunate to dihydroartemisinin in pregnant vs. postâ€partum patients with malaria after oral artesunate dosing?. British Journal of Clinical Pharmacology, 2016, 81, 389-390.	2.4	4
108	Should commonly prescribed drugs be avoided as internal standard choices in new assays for clinical samples?. Bioanalysis, 2016, 8, 607-610.	1.5	17

#	Article	IF	Citations
109	Intranasal Pharmacokinetic Data for Triptans Such as Sumatriptan and Zolmitriptan Can Render Area Under the Curve (AUC) Predictions for the Oral Route: Strategy Development and Application. Journal of Pain and Palliative Care Pharmacotherapy, 2016, 30, 13-24.	0.8	2
110	Prediction of area under the concentrationâ€“time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavirâ€“ritonavir therapy. American Journal of Health-System Pharmacy, 2016, 73, 376-385.	1.0	2
111	Relationship Between Buprenorphine Dosing and Triglyceride Lowering and Creatinine Kinase Elevation in Felines: Possible Human Implications. Journal of Pain and Palliative Care Pharmacotherapy, 2016, 30, 49-52.	0.8	1
112	Interspecies scaling of excretory amounts using allometry â€“ retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion. Xenobiotica, 2016, 46, 784-792.	1.1	4
113	The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?. Pharmaceutical Research, 2016, 33, 543-547.	3.5	3
114	The pharmacokinetic disposition of delta-9-tetrahydrocannabinol and its metabolite in elderly patients with dementiaâ€”role of differential presystemic conversion?. Psychopharmacology, 2016, 233, 157-158.	3.1	1
115	Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites. Drug Development and Industrial Pharmacy, 2016, 42, 945-957.	2.0	11
116	Limited Sampling Strategy for the Prediction of Area Under the Curve (AUC) of Statins: Reliability of a Single Time Point for AUC Prediction for Pravastatin and Simvastatin. Drug Research, 2016, 66, 82-93.	1.7	7
117	Gastric emptying and acetaminophen: lessons learnt from the several co-administered drugs on the experimental design. European Journal of Clinical Pharmacology, 2016, 72, 369-371.	1.9	0
118	Commonality of rituximab pharmacokinetic disposition in nephrotic syndrome and autoimmune cytopenias in chronic lymphocytic leukemia patients. Pediatric Nephrology, 2016, 31, 335-336.	1.7	2
119	Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Cannalicular Efflux Transporters?. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 563-563.	2.5	2
120	Letter: gluten digestion in the stomach and duodenum by Aspergillus nigerâ€derived enzyme â€“ things to ponder. Alimentary Pharmacology and Therapeutics, 2015, 42, 946-946.	3.7	1
121	Comment on: â€œPharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selectionâ€. Clinical Pharmacokinetics, 2015, 54, 1293-1295.	3.5	2
122	Firstâ€inâ€man study of ACTâ€453859, a potent CRTH2 antagonistâ€”Is the metabolite formation influenced by a polymorphic enzyme?. Journal of Clinical Pharmacology, 2015, 55, 1432-1432.	2.0	1
123	Linagliptinâ€”Role in the Reversal of AÎ²â€Mediated Impairment of Insulin Signaling and Reduced Neurotoxicity in <scp>AD</scp> Pathogenesis: Some Considerations. CNS Neuroscience and Therapeutics, 2015, 21, 962-963.	3.9	6
124	Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data. Biopharmaceutics and Drug Disposition, 2015, 36, 575-586.	1.9	16
125	Oral tramadol pharmacokinetics in pediatric subjects versus adultsâ€”Is there a role of delayed gastric emptying in pediatric subjects?. Clinical Pharmacology in Drug Development, 2015, 4, 473-474.	1.6	1
126	Recent trends in preclinical drugâ€“drug interaction studies of flavonoidsâ€‰â€”â€‰Review of case studies, issues and perspectives. Phytotherapy Research, 2015, 29, 1679-1691.	5.8	43

#	Article	IF	Citations
127	Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles â€“ Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 434.	2.1	5
128	Letter: infliximab therapy for patients with inflammatory bowel disease â€“ some unanswered questions. Alimentary Pharmacology and Therapeutics, 2015, 42, 1133-1133.	3.7	1
129	Schedule-dependent modulation of the pharmacokinetics of MK-2206, an oral pan-AKT inhibitor: perspectives. Cancer Chemotherapy and Pharmacology, 2015, 76, 1315-1316.	2.3	0
130	Fidaxomicin Pharmacokinetics in Humans: Is There a Role of Biliary Excretion?. Clinical Drug Investigation, 2015, 35, 531-532.	2.2	0
131	Biochanin A: Understanding the Complexities in the Paradoxical Drugâ€“Drug Interaction Potential. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 119-125.	1.6	15
132	Comment on: â€œPharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipagâ€• American Journal of Cardiovascular Drugs, 2015, 15, 371-372.	2.2	1
133	Phenylephrine Pharmacokinetics and First-Pass Metabolism: What Is an Ideal Pharmacokinetic Surrogate?. Clinical Drug Investigation, 2015, 35, 851-853.	2.2	0
134	Acetaminophen Absorption Kinetics in Altered Gastric Emptying: Establishing a Relevant Pharmacokinetic Surrogate Using Published Data. Journal of Pain and Palliative Care Pharmacotherapy, 2015, 29, 115-119.	0.8	12
135	Bioanalysis in oncology drug discovery. Biomarkers in Medicine, 2015, 9, 877-886.	1.4	6
136	Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6â€“Mediated Substrate. Journal of Pain and Palliative Care Pharmacotherapy, 2015, 29, 272-275.	0.8	3
137	Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors â€“ review of assay methodologies and perspectives. Biomedical Chromatography, 2015, 29, 803-834.	1.7	34
138	Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 1-12.	1.6	9
139	Dilemma with Matrix Effect in Bioanalysis â€“ Perspectives from Bioavailability/Bioequivalence Studies for Product Registration?. Drug Research, 2014, 64, 335-336.	1.7	4
140	Transdermal buprenorphineâ€”interesting observations on the metabolite norbuprenorphine levels in elderly subjects. European Journal of Clinical Pharmacology, 2013, 69, 1607-1608.	1.9	0
141	New lumefantrine self nanoemulsifying delivery system â€“ will it by-pass lymphatic transport mechanisms?. DARU, Journal of Pharmaceutical Sciences, 2013, 21, 55.	2.0	0
142	Commentary on: â€œstudy of the pharmacokinetic changes of tramadol in diabetic ratsâ€•is the handicapped renal pathway in DMIS contributing for the increased bioavailability of tramadol?. DARU, Journal of Pharmaceutical Sciences, 2013, 21, 23.	2.0	1
143	The reâ€•emergence of saltingâ€•out association with acetonitrile for modern day bioanalysis. Biomedical Chromatography, 2013, 27, 545-547.	1.7	4
144	Is pomegranate juice a potential perpetrator of clinical drugâ€“drug interactions? Review of the in vitro, preclinical and clinical evidence. European Journal of Drug Metabolism and Pharmacokinetics, 2013, 38, 223-229.	1.6	29

#	Article	IF	Citations
145	Phase I and beyond â€“ the importance of switching to patientâ€™s plasma: considerations and perspectives on bioanalytical procedures. Bioanalysis, 2013, 5, 2215-2218.	1.5	0
146	Review of the quantitative analysis of cholesteryl ester transfer protein inhibitors. Biomedical Chromatography, 2013, 27, 1259-1272.	1.7	2
147	Do We Have Clarity on the Therapeutic Levels of Morphine and Its Metabolites: Seeking Answers for the Dilemma?. Journal of Pain and Palliative Care Pharmacotherapy, 2013, 27, 163-166.	0.8	2
148	Cranberry Juice Ingestion and Clinical Drug-Drug Interaction Potentials; Review of Case Studies and Perspectives. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 289.	2.1	42
149	The Observed Correlation between in vivo Clinical Pharmacokinetic Parameters and in vitro Potency of VEGFR-2 Inhibitors. Arzneimittelforschung, 2012, 62, 194-201.	0.4	12
150	A strategy for extending the applicability of a validated plasma calibration curve to quantitative measurements in multiple tissue homogenate samples: a case study from a rat tissue distribution study of JI-101, a triple kinase inhibitor. Biomedical Chromatography, 2012, 26, 419-424.	1.7	2
151	Review of HPLC methods and HPLC methods with mass spectrometric detection for direct determination of aspirin with its metabolite(s) in various biological matrices. Biomedical Chromatography, 2012, 26, 906-941.	1.7	20
152	Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study. Biomedical Chromatography, 2012, 26, 232-238.	1.7	2
153	Pharmacokinetics of Tolbutamide in Acute Renal Failure Induced by Glycerol: Speculative Thoughts and Perspectives. Drug Metabolism and Pharmacokinetics, 2011, 26, 216-217.	2.2	4
154	PK/PD modeling of rabeprazole in CYP2C19 genotypes: consideration of the influence of thio-ether metabolite, CYP3A4, accumulation and CYP2D6 polymorphism may help to better develop and validate the model. European Journal of Clinical Pharmacology, 2011, 67, 965-966.	1.9	1
155	Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36, 87-93.	1.6	3
156	The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36, 49-59.	1.6	10
157	Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study. Biomedical Chromatography, 2011, 25, 794-800.	1.7	2
158	An overview of various validated HPLC and LCâ€MS/MS methods for quantitation of drugs in bile: challenges and considerations. Biomedical Chromatography, 2011, 25, 65-81.	1.7	13
159	Incurred sample reanalysis: dilemma in its applicability â€“ should it be practiced for all bioanalytical assays involving single (parent or metabolite) or multiple analytes (parent/metabolite or parent with) Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	3
160	Dealing with matrix effect: should there be a cutâ€off limit for signal ion suppression in quantitative assay validation?. Biomedical Chromatography, 2011, 25, 740-742.	1.7	5
161	Sensitivity enhancement and matrix effect evaluation during summation of multiple transition pairsâ€”case studies of clopidogrel and ramiprilat. Biomedical Chromatography, 2010, 24, 528-534.	1.7	14
162	Influence of number of calibration standards within a defined range on pharmacokinetic dispositionâ€”case studies with omeprazole and clopidogrel carboxylic acid. Biomedical Chromatography, 2010, 24, 544-549.	1.7	3

#	Article	IF	Citations
163	Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypesâ€“focus on venlafaxine and O-desmethylvenlafaxine. European Journal of Clinical Pharmacology, 2010, 66, 879-887.	1.9	19
164	Irinotecan and its active metabolite, SNâ€38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomedical Chromatography, 2010, 24, 104-123.	1.7	139
165	Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives. Arzneimittelforschung, 2010, 60, 731-748.	0.4	8
166	Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica, 2010, 40, 357-367.	1.1	113
167	Antacid Use and Reduced Bioavailability of Oral Drugs. Arzneimittelforschung, 2009, 59, 327-334.	0.4	2
168	Torcetrapib for animal and human pharmacokinetic studies: applicability of chiral and achiral methodologies. Bioanalysis, 2009, 1, 619-628.	1.5	2
169	Considerations for Metabolite Pharmacokinetic Data in Bioavailability/Bioequivalence Assessments. Arzneimittelforschung, 2009, 59, 155-165.	0.4	6
170	Structurally Modified ‘Dietary Flavonoids’: Are these Viable Drug Candidates for Chemoprevention?. Current Clinical Pharmacology, 2009, 4, 67-70.	0.6	12
171	Prediction of Human Pharmacokinetic Parameters Using Animal Data and Principles of Allometry. Arzneimittelforschung, 2009, 59, 625-630.	0.4	3
172	Drugâ€“drug interaction studies in preclinical species: should metabolite(s) kinetics be studied?. Xenobiotica, 2009, 39, 193-196.	1.1	4
173	Unsuspected and Paradoxical Potential for Drug Interaction by Rifampin: Things to Ponder with Antiretroviral Therapy. Journal of Infectious Diseases, 2009, 199, 766-767.	4.0	7
174	Sensitivity enhancement in tandem liquid chromatographic mass spectrometric assays by summation of two transition ion pairs â€“ perspectives. Journal of Separation Science, 2009, 32, 483-486.	2.5	14
175	New thinking in the development of novel derivatization reagents for liquid chromatographyâ€“mass spectrometric detection. Biomedical Chromatography, 2009, 23, 107-108.	1.7	8
176	Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives. Biomedical Chromatography, 2009, 23, 3-25.	1.7	41
177	Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drugâ€“drug interaction studies. Biomedical Chromatography, 2009, 23, 26-41.	1.7	46
178	Dodging matrix effects in liquid chromatography tandem mass spectrometric assaysâ€”compilation of key learnings and perspectives. Biomedical Chromatography, 2009, 23, 451-454.	1.7	64
179	Enhancement of the impact of manuscript submissions toBMC: an editorial perspective. Biomedical Chromatography, 2009, 23, 1-2.	1.7	1
180	Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives. Biomedical Chromatography, 2009, 23, 677-691.	1.7	6

#	Article	IF	Citations
181	Bioanalytical assay validation parameters reâ€visited: perspectives on stability studies. Biomedical Chromatography, 2009, 23, 1031-1033.	1.7	0
182	LC/MS/MS analysis of capsaicin using multiple transition pairsâ€"some view points to ponder. Biomedical Chromatography, 2009, 23, 1129-1130.	1.7	3
183	Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain â€" Biopharmaceutic and pharmacokinetic challenges. European Journal of Drug Metabolism and Pharmacokinetics, 2009, 34, 7-10.	1.6	1
184	Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor. European Journal of Drug Metabolism and Pharmacokinetics, 2009, 34, 57-63.	1.6	5
185	Tigecycline and cyclosporine interactionâ€"an interesting case of biliary-excreted drug enhancing the oral bioavailability of cyclosporine. European Journal of Clinical Pharmacology, 2009, 65, 543-544.	1.9	11
186	Efflux Transporterâ€Mediated Interactions With Atorvastatinâ€"Interesting Findings With Multiple Substrates: Istradefylline, Verapamil, and Rifampicin. Journal of Clinical Pharmacology, 2009, 49, 1492-1493.	2.0	3
187	Digoxin â€“ a therapeutic agent and mechanistic probe: review of liquid chromatographic mass spectrometric methods and recent nuances in the clinical pharmacology attributes of digoxin. Bioanalysis, 2009, 1, 97-113.	1.5	11
188	Is There a Place for Drug Combination Strategies Using Clinical Pharmacology Attributes? â€“ Review of Current Trends in Research. Current Clinical Pharmacology, 2009, 4, 220-228.	0.6	5
189	Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 247-252.	1.6	8
190	Allometric prediction of the human pharmacokinetic parameters for naveglitazar. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 187-190.	1.6	6
191	Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil. European Journal of Clinical Pharmacology, 2008, 64, 1135-1136.	1.9	12
192	Applicability of nonlinear calibration regression for quantitative determination of parent and metabolite(s) in bioequivalence assessment. Biomedical Chromatography, 2008, 22, 1315-1317.	1.7	7
193	A rapid and highly sensitive method for the determination of glimepiride in human plasma by liquid chromatographyâ€"electrospray ionization tandem mass spectrometry: application to a preâ€clinical pharmacokinetic study. Biomedical Chromatography, 2008, 22, 58-63.	1.7	30
194	Changing need for bioanalysis during drug development. Biomedical Chromatography, 2008, 22, 235-243.	1.7	24
195	Development and validation of a sensitive LCâ€MS/MS method with electrospray ionization using multiple ions for quantitation of torcetrapib in hamster and dog plasma. Biomedical Chromatography, 2008, 22, 316-326.	1.7	11
196	Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of rhein in human plasma: application to a pharmacokinetic study. Biomedical Chromatography, 2008, 22, 616-624.	1.7	31
197	Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data. Xenobiotica, 2008, 38, 1377-1385.	1.1	9
198	Development and Validation of a Highly Sensitive and Robust LC-MS/MS with Electrospray Ionization Method for Quantification of Rosuvastatin in Small Volume Human Plasma Samples and its Application to a Clinical Study. Arzneimittelforschung, 2007, 57, 705-711.	0.4	14

#	Article	IF	Citations
199	Concurrent determination of ezetimibe and its phase-I and II metabolites by HPLC with UV detection: Quantitative application to various in vitro metabolic stability studies and for qualitative estimation in bile. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 853, 88-96.	2.3	41
200	Development and validation of an enantioselective HPLCâ€“UV method using Chiralpak AD-H to quantify (+)- and (â^')-torcetrapib enantiomers in hamster plasmaâ€”application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 857, 224-230.	2.3	8
201	Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. European Journal of Drug Metabolism and Pharmacokinetics, 2007, 32, 29-37.	1.6	13
202	Chiral bioanalysis of torcetrapib enantiomers in hamster plasma by normal-phase liquid chromatography and detection by atmospheric pressure chemical ionization tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 860, 227-234.	2.3	7
203	Bioavailability Enhancement of Poorly Water Soluble and Weakly Acidic New Chemical Entity with 2-Hydroxy Propyl-Î²-Cyclodextrin: Selection of Meglumine, a Polyhydroxy Base, as a Novel Ternary Component. Pharmaceutical Development and Technology, 2006, 11, 443-451.	2.4	15
204	Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. Biomedical Chromatography, 2006, 20, 125-132.	1.7	37
205	Analysis of five HMG-CoA reductase inhibitorsâ€" atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis andin vitro metabolism studies. Biomedical Chromatography, 2006, 20, 282-293.	1.7	91
206	High-performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of ratin situ intestinal permeability studies using timed wavelength detection. Biomedical Chromatography, 2006, 20, 349-357.	1.7	17
207	Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomedical Chromatography, 2006, 20, 383-414.	1.7	55
208	Determination of rosuvastatin in rat plasma by HPLC: validation and its application to pharmacokinetic studies. Biomedical Chromatography, 2006, 20, 881-887.	1.7	56
209	Simultaneous estimation of six anti-diabetic drugsâ€"glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay. Biomedical Chromatography, 2006, 20, 1043-1048.	1.7	78
210	Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. Biomedical Chromatography, 2006, 20, 1252-1259.	1.7	37
211	Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: Impact on oral bioavailability, absorption, and metabolic disposition in rats. Xenobiotica, 2006, 36, 838-856.	1.1	11
212	Validated HPLC analytical method with programmed wavelength UV detection for simultaneous determination of DRF-4367 and Phenol red in rat in situ intestinal perfusion study. Journal of Pharmaceutical and Biomedical Analysis, 2005, 38, 173-179.	2.8	15
213	Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LCâ€“MS/MS with electrospray ionization: Assay development, validation and application to a clinical study. Journal of Pharmaceutical and Biomedical Analysis, 2005, 39, 661-669.	2.8	73
214	METABOLISM, PHARMACOKINETICS, AND PROTEIN COVALENT BINDING OF RADIOLABELED MAXIPOST (BMS-204352) IN HUMANS. Drug Metabolism and Disposition, 2005, 33, 83-93.	3.3	50
215	Safety, Tolerability, and Pharmacokinetics of a Capsule Formulation of DRF-1042, a Novel Camptothecin Analog, in Refractory Cancer Patients in a Bridging Phase I Study. Journal of Clinical Pharmacology, 2005, 45, 453-460.	2.0	16
216	Bioanalytical Aspects in Characterization and Quantification of Glucuronide Conjugates in Various Biological Matrices. Current Pharmaceutical Analysis, 2005, 1, 251-264.	0.6	15

#	Article	IF	Citations
217	Role of Stereoselective Assays in Bioequivalence Studies of Racemic Drugs: Have We Reached a Consensus?. Journal of Clinical Pharmacology, 2004, 44, 115-119.	2.0	9
218	Evaluation of experimental strategies for the development of chiral chromatographic methods based on diastereomer formation. Biomedical Chromatography, 2004, 18, 207-233.	1.7	67
219	Determination of lipoic acid in rat plasma by LC-MS/MS with electrospray ionization: Assay development, validation and application to a pharamcokinetic study. Biomedical Chromatography, 2004, 18, 681-686.	1.7	37
220	Clinical pharmacokinetic data of racemic drugs obtained by the indirect method following precolumn diastereomer formation: is the influence of racemization during chiral derivatization significant?. Biomedical Chromatography, 2004, 18, 343-349.	1.7	14
221	Simultaneous chiral analyses of multiple analytes: case studies, implications and method development considerations. Biomedical Chromatography, 2004, 18, 759-784.	1.7	28
222	Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones. Xenobiotica, 2004, 34, 571-579.	1.1	13
223	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF-1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study. Journal of Clinical Pharmacology, 2004, 44, 723-736.	2.0	16
224	Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics. Biomedical Chromatography, 2003, 17, 385-390.	1.7	9
225	Bioanalytical considerations for compounds containing free sulfhydryl groups. Biomedical Chromatography, 2003, 17, 285-291.	1.7	28
226	Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. Biomedical Chromatography, 2003, 17, 417-420.	1.7	32
227	Resolution of enantiomers of ketoprofen by HPLC: a review. Biomedical Chromatography, 2003, 17, 423-434.	1.7	31
228	â€˜Open accessâ€™ generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies. Xenobiotica, 2003, 33, 1233-1245.	1.1	15
229	Lack of Effect of Sucralfate on the Absorption and Pharmacokinetics of Rosiglitazone. Journal of Clinical Pharmacology, 2002, 42, 670-675.	2.0	14
230	Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. Biopharmaceutics and Drug Disposition, 2002, 23, 273-282.	1.9	28
231	Quantitation of itraconazole in rat heparinized plasma by liquid chromatographyâ€“mass spectrometry. Biomedical Applications, 2001, 752, 9-16.	1.7	41
232	Enantiomeric drug development: Issues, considerations, and regulatory requirements. Journal of Pharmaceutical Sciences, 2001, 90, 1205-1215.	3.3	61
233	Sensitive liquid chromatographicâ€“mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring. Biomedical Applications, 1998, 718, 77-85.	1.7	17
234	Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. Pharmaceutical Research, 1997, 14, 911-916.	3.5	12

#	Article	IF	Citations
235	Bioequivalence of Two Tablet Formulations of Nadolol Using Single and Multiple Dose Data: Assessment Using Stereospecific and Nonstereospecific Assays. Journal of Pharmaceutical Sciences, 1996, 85, 299-303.	3.3	19
236	Phase I and pharmacokinetic study of etoposide phosphate. Anti-Cancer Drugs, 1995, 6, 637-644.	1.4	16
237	Gas chromatographic determination of enantiomers as diastereomers following pre-column derivatization and applications to pharmacokinetic studies: A review. Biomedical Chromatography, 1995, 9, 1-9.	1.7	46
238	Simultaneous determination of nadolol enantiomers in human plasma by high-performance liquid chromatography using fluorescence-detection. Biomedical Chromatography, 1995, 9, 140-145.	1.7	18
239	A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days*. Clinical Pharmacology and Therapeutics, 1995, 57, 499-507.	4.7	21
240	Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharmaceutical Research, 1993, 10, 14-21.	3.5	97
241	Enantioselective pharmacokinetics and pharmacodynamics of dl-thero-mcthylphenidate in children with attention deficit hyperactivity disorder. Clinical Pharmacology and Therapeutics, 1992, 52, 561-568.	4.7	116
242	Chiral separation by high performance liquid chromatography. I. Review on indirect separation of enantiomers as diastereomeric derivatives using ultraviolet, fluorescence and electrochemical detection. Biomedical Chromatography, 1992, 6, 163-167.	1.7	48
243	Stereoselective Urinary Pharmacokinetics of dl-threo-Methylphenidate and Its Major Metabolite in Humans. Journal of Pharmaceutical Sciences, 1992, 81, 747-749.	3.3	24
244	Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1991, 15, 213-220.	4.8	31
245	Evidence that Dogs Do Not Model Enantioselective Pharmacokinetics of dl-Methylphenidate in Humans. Journal of Pharmaceutical Sciences, 1991, 80, 707-708.	3.3	14
246	In vitro hydrolysis of RR,SS-threo-methylphenidate by blood esterases?differential and enantioselective interspecies variability. Chirality, 1991, 3, 99-103.	2.6	35
247	Enantioselective gas chromatographic assay with electron-capture detection for dl-ritalinic acid in plasma. Biomedical Applications, 1990, 530, 327-336.	1.7	25
248	Enantioselective Aspects of the Disposition of dl-threo-Methylphenidate after the Administration of a Sustained-Release Formulation to Children with Attention Deficit-Hyperactivity Disorder. Journal of Pharmaceutical Sciences, 1989, 78, 944-947.	3.3	49
249	Enantioselective gas chromatographic assays with electron-capture detection for methoxyphenamine and its three primary metabolites in human urine. Biomedical Applications, 1989, 487, 61-72.	1.7	13
250	Enantioselective gas chromatographic assay with electron-capture detection for dl-fenfluramine and dl-norfenfluramine in plasma. Biomedical Applications, 1988, 433, 105-117.	1.7	14
251	Stereoselective disposition of methylphenidate in children with attention-deficit disorder. Journal of Pharmacology and Experimental Therapeutics, 1987, 241, 300-6.	2.5	51